Amid rising healthcare costs, the federal government is taking definitive steps to alleviate the financial burden on seniors by slashing Medicare drug prices. A recent announcement revealed that price reductions for 15 drugs will take effect in 2027, promising savings for millions.
The negotiated prices include a significant 71% discount on popular diabetes and obesity medications such as Ozempic, Wegovy, and Rybelsus, which currently have high monthly costs. In addition to these, drugs treating conditions like asthma, breast cancer, and leukemia are also part of the negotiation, with discounts ranging from 38% for Austedo to a hefty 85% for Janumet.
Health and Human Services Secretary Robert F. Kennedy, Jr. emphasized the administration’s commitment, stating, “President Trump directed us to stop at nothing to lower health care costs for the American people.” This initiative aligns with the broader agenda to enhance affordable health care for seniors.
These negotiations are part of a broader legislative effort initiated by the Inflation Reduction Act of 2022, which lifted a longstanding restriction on Medicare’s ability to negotiate drug prices, despite lacking bipartisan support. The first set of drug prices was negotiated last year under this act.
According to the Centers for Medicare and Medicaid Services (CMS), if these newly negotiated prices had been effective in 2024, the savings would amount to $12 billion. Dr. Benjamin Rome, a health policy expert, notes that this year’s savings surpass the previous year’s due to the types of drugs involved and accumulated negotiation experience.
These drugs were selected based on their high Medicare spending, absence of generic alternatives, and extended market presence. Notably, the reduced prices for Ozempic and Wegovy follow a separate agreement announced by the Trump administration with Novo Nordisk, the manufacturer of these drugs.
Confusion arises from differing discount rates between the Medicare negotiations and the earlier agreement with Novo Nordisk, which had set lower monthly prices for these medications. Dr. Rome expressed uncertainty over why varied pricing exists in different agreements.
Novo Nordisk remains committed to advocating for drug affordability, despite concerns over government-imposed pricing as outlined in the Inflation Reduction Act. Their statement also highlights an initiative to broaden obesity care access within Medicare and Medicaid.
The AARP, representing Americans aged 50 and above, commended the price negotiations. Dr. Myechia Minter-Jordan, AARP’s CEO, remarked, “Today’s announcement marks yet another significant next step forward in our long-standing efforts to lower prescription drug prices.” The new prices are expected to provide substantial relief to Medicare beneficiaries across the political spectrum.
Copyright 2025 NPR
—
Read More Michigan News
